Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Cash & Equivalents (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Cash & Equivalents for 11 consecutive years, with $125.1 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 41.14% to $125.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $125.1 million through Dec 2025, down 41.14% year-over-year, with the annual reading at $125.1 million for FY2025, 41.14% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $125.1 million at Cartesian Therapeutics, down from $143.4 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $219.2 million in Q3 2024, with the low at $76.9 million in Q4 2023.
  • Average Cash & Equivalents over 5 years is $128.8 million, with a median of $119.9 million recorded in 2021.
  • The sharpest move saw Cash & Equivalents soared 176.44% in 2024, then crashed 41.14% in 2025.
  • Over 5 years, Cash & Equivalents stood at $114.1 million in 2021, then fell by 6.68% to $106.4 million in 2022, then decreased by 27.74% to $76.9 million in 2023, then skyrocketed by 176.44% to $212.6 million in 2024, then tumbled by 41.14% to $125.1 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $125.1 million, $143.4 million, and $160.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.